menu
    • menu

    Company profile for LintonPharm

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm, in collaboration with Lindis Biotech, is developing catumaxomab for use in a broad range of cancers globally. Additionally, LintonPharm is developing a next generation...
    LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. LintonPharm, in collaboration with Lindis Biotech, is developing catumaxomab for use in a broad range of cancers globally. Additionally, LintonPharm is developing a next generation bispecific antibody platform to provide a more robust manufacturing and drug design and increased flexibility to individualize the design of each molecule.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    LintonPharmChina Flag
    Country
    Country
    China
    Address
    Address
    B, No.19 NanXiang 3rd Road, Guangzhou
    Telephone
    Telephone
    (020)-31801890
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.lintonpharm.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer
    LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer

    27 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220527005174/en

    BUSINESSWIRE
    27 May 2022
    Share Share
    LintonPharm Begins Dosing in Phase 1 Clinical Trial of Catumaxomab
    LintonPharm Begins Dosing in Phase 1 Clinical Trial of Catumaxomab

    01 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211201005307/en

    BUSINESSWIRE
    01 Dec 2021
    Share Share
    LintonPharm Announces Authorization from China Health (NMPA) t Catumaxomab
    LintonPharm Announces Authorization from China Health (NMPA) t Catumaxomab

    14 Apr 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210413005114/en

    BUSINESSWIRE
    14 Apr 2021
    Share Share
    LintonPharm Announces Authorization from China Health Authority (NMPA)
    LintonPharm Announces Authorization from China Health Authority (NMPA)

    14 Apr 2021

    // BUSINESSWIREINDIA

    https://www.businesswireindia.com/lintonpharm-announces-authorization-from-china-health-authority-nmpa-to-proceed-with-a-phase-1by2-trial-evaluating-catumaxomab-for-the-treatment-of-non-muscle-invasive-bladder-cancer-72506.html

    BUSINESSWIREINDIA
    14 Apr 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search